How common is safety in humans with BPC-157?

What the studies show

Two healthy adults given intravenous doses in an uncontrolled 2025 pilot showed no biomarker changes. That is the entire human safety literature.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

1. 1
   Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review.HSS Journal, 2025;21(4):485–495544 articles screened; 36 included — 35 preclinical, 1 clinical (a 12-patient retrospective case report). No clinical safety data found.
2. 2
   Lee E, Burgess J. Intravenous BPC-157 in healthy adults: an open-label pilot.2025 (pilot, n = 2)Uncontrolled; biomarkers only; no efficacy endpoints. Same research group as other human reports.
3. 3
   U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (BPC-157).FDA, 2023Regulatory status in the United States.

In context

BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. In rodents it consistently speeds healing of tendon, ligament, muscle and gut injury. In people it has never been tested in a controlled trial, so every human claim about it — healing, pain relief, safety — is currently unproven. It is not an approved medicine anywhere and is prohibited in sport.

BPC-157 is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Other outcomes for BPC-157

• DTendon & ligament healing0 controlled
• DGut mucosal healing0 controlled
• DPain reduction1 case series (n=12)

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →